Dr. Wolchok Explains the Future of Ipilimumab

Jedd D. Wolchok, MD, PhD
Published: Friday, Jun 17, 2011

Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center explains the future of ipilimumab.

Dr. Wolchok says that, in general, ipilimumab releases a breaking mechanism on the immune system. He says it's versatile in that it could have activity in diseases other than melanoma because it doesn't specifically release an immune response to melanoma. It does release an immune response to melanoma, but there are ongoing studies using ipilimumab in prostate cancer and there have been smaller experiences in ovary cancer and kidney cancer. This brings up the possibility that it could be applied in other disease settings.
SELECTED
LANGUAGE
Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center explains the future of ipilimumab.

Dr. Wolchok says that, in general, ipilimumab releases a breaking mechanism on the immune system. He says it's versatile in that it could have activity in diseases other than melanoma because it doesn't specifically release an immune response to melanoma. It does release an immune response to melanoma, but there are ongoing studies using ipilimumab in prostate cancer and there have been smaller experiences in ovary cancer and kidney cancer. This brings up the possibility that it could be applied in other disease settings.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x